Quarterly report pursuant to Section 13 or 15(d)

Stock-based Compensation (Details)

Stock-based Compensation (Details) - USD ($)
$ / shares in Millions, $ in Millions
1 Months Ended 9 Months Ended 12 Months Ended
Apr. 06, 2020
Feb. 17, 2021
Jul. 31, 2019
Sep. 30, 2021
Dec. 31, 2020
Dec. 31, 2019
Jul. 15, 2021
Stock-based Compensation (Details) [Line Items]              
Common stock, shares reserved for issuance             1,302,326
Authorized for issuance of shares     1,159,065        
Increase in issuance of authorized shares 348,837 1,767,442   33,263 33,263    
authorized for issuance         465,116    
Shares available for future grant         17,442    
Fair value of options granted (in Dollars per share)       $ 1.3      
Unrecognized compensation cost (in Dollars)       $ 1.5      
Weighted average period       2 years 8 months 12 days      
Expected dividend       0.00%      
Compensation cost description       During July 2021, in connection with the appointment of Dr. Brigitte Schiller to the Company’s board of directors, the Company granted Dr. Schiller 17,882 stock options with a ten year term, an exercise price of $5.00 per option, and a total fair value of $50,000 on the date of grant. Additionally, the Company granted Dr. Schiller 26,738 restricted stock units with a grant date fair value of $100,000. Subject to Dr. Schiller’s continued service, such options and restricted stock units shall vest upon the one-year anniversary of the date of grant. As of September 30, 2021, the unrecognized compensation cost related to outstanding restricted stock units was $0.1 million, which is expected to be recognized as expense over approximately 9 months.       
Two Thousand Nineteen [Member]              
Stock-based Compensation (Details) [Line Items]              
Authorized for issuance of shares           232,558  
Shares issued for future grants           75,581